Book contents
- Frontmatter
- Contents
- Contributors
- Preface
- Section one Overviews
- Section two Molecules for Chemical Genomics
- Section Three Basics of High-Throughput Screening
- Section Four Chemical Genomics Assays and Screens
- Section five Chemical Genomics and Medicine
- Chapter 21 Pharmacogenomics to Link Genetic Background with Therapeutic Efficacy and Safety
- Chapter 22 Drugs, Genomic Response Signatures, and Customized Cancer Therapy
- Chapter 23 Current Drug Targets and the Druggable Genome
- Index
- References
Chapter 21 - Pharmacogenomics to Link Genetic Background with Therapeutic Efficacy and Safety
from Section five - Chemical Genomics and Medicine
Published online by Cambridge University Press: 05 June 2012
- Frontmatter
- Contents
- Contributors
- Preface
- Section one Overviews
- Section two Molecules for Chemical Genomics
- Section Three Basics of High-Throughput Screening
- Section Four Chemical Genomics Assays and Screens
- Section five Chemical Genomics and Medicine
- Chapter 21 Pharmacogenomics to Link Genetic Background with Therapeutic Efficacy and Safety
- Chapter 22 Drugs, Genomic Response Signatures, and Customized Cancer Therapy
- Chapter 23 Current Drug Targets and the Druggable Genome
- Index
- References
Summary
Pharmacogenomics (PGx) is a rapidly evolving science with the potential to transform the way in which medicines are developed and prescribed. It represents a new era in patient treatment and will enable delivery of medicines in a safer and more efficacious manner. The aim of PGx is to optimize drug therapy with respect to the individual's genetic profile by associating genetic markers (e.g., single-nucleotide polymorphisms [SNPs] or gene expression) with the drug's safety or efficacy, thereby heralding the advent of personalized medicine (the right drug for the right person), whereby a drug may be selected or optimized for a specific individual based on his or her genetic characteristics. Recent advances, approaches, technologies, and resources in this field are highlighted in this chapter and interlaced with established and new exemplars.
Definition
Often, the term pharmacogenomics is used interchangeably with pharmacogenetics, and it has proved difficult to define each concisely. However, it is generally accepted that pharmacogenomics takes into account the whole genome in a wide application of genomic technologies used to predict drug efficacy and safety in order to characterize current drugs or discover new drugs while considering genetic variation, whereas PGx is seen as the study of inherited genetic variation that may be associated with different response or adverse events to drugs by assessing typically one or a few candidate genes.
- Type
- Chapter
- Information
- Chemical Genomics , pp. 293 - 300Publisher: Cambridge University PressPrint publication year: 2012